Trial Profile

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liradasertib (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms LUMA
Sponsors Biogen

Most Recent Events

29 May 2026 Status changed from active, no longer recruiting to completed.
21 May 2026 According to a Biogen and Denali Therapeutics Media Release, detailed findings from the LUMA study at an upcoming scientific conference.
21 May 2026 According to a Biogen and Denali Therapeutics Media Release, will discontinue further development of BIIB122 in idiopathic Parkinson's disease.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com